Human Anti-TNFRSF10B Recombinant Antibody (clone TRA-8) (CAT#: HPAB-1180WJ)

Figure 1 Cytotoxicity of TRA-8 against prostate cancer cell lines.

Three different prostate cancer cell lines (PC-3, DU145, and LnCap) were plated in 96-well plates at a concentration of 5000 cells/well. Cells were treated with TRA-8 at different concentrations (0-1000 ng/ml), and assayed for survival using the ATPLite assay.

Arafat, W., Zhou, T., Naoum, G. E., & Buchsbaum, D. J. (2015). Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer. Journal of the Egyptian National Cancer Institute, 27(4), 205-215.

Figure 2 Combined TRA-8 and AdVEGFBax treatment increased cytotoxicity to cancer cells.

U251MG cells were treated with different combinations of AdVEGFBax or AdVEGFEGFP (as viral control) and TRA-8 antibody. Cells were washed with DPBSS 2 h after adenovirus infection and antibody was added with complete media. Cell viability was determined at 96 h after treatment by using the MTS assay.

Kaliberov, S., Stackhouse, M. A., Kaliberova, L., Zhou, T., & Buchsbaum, D. J. (2004). Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. Gene therapy, 11(8), 658-667.

Figure 3 Bax and DR5 expression in treated cells. PC-3 prostate cancer cells (2 × 105) were plated in 6-well plates.

Cells were cytospinned and incubated with bax and DR-5 antibodies, followed by a fluorescent secondary antibody, and visualized by fluorescent microscopy. Green color indicates bax. Blue color indicates nucleolus and red color is DR5.

Arafat, W., Zhou, T., Naoum, G. E., & Buchsbaum, D. J. (2015). Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer. Journal of the Egyptian National Cancer Institute, 27(4), 205-215.

Figure 4 Treatment of PC-3 xenografts with TRA-8 and radiation.

Athymic nude mice were injected s.c. with 3 × 10⁷ PC-3 cells. At 7 days after tumor cell injection, 200 μg TRA-8 was administered i.p. followed by five additional injections on days 10, 14, 17, 21, and 24.

Arafat, W., Zhou, T., Naoum, G. E., & Buchsbaum, D. J. (2015). Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer. Journal of the Egyptian Nationalancer Institute, 27(4), 205-215.

Figure 5 The level of expression of the DR5 protein in brain cell lines. The expression of DR5 and actin proteins was examined using a Western blotting analysis.

Kaliberov, S., Stackhouse, M. A., Kaliberova, L., Zhou, T., & Buchsbaum, D. J. (2004). Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. Gene therapy, 11(8), 658-667.

Figure 6 Growth of U251MG human glioma xenografts treated with AdVEGFBax and TRA-8 alone or in combination.

Treatment was started at the time of established tumor growth (day 0). Animals were injected i.t. with 2 x 10⁸ PFU/tumor AdVEGFEGFP or AdVEGFBax on days 0, 7 and 14, and treated i.p. with TRA-8 (200 mg/mouse) or 100 ml PBS (control) on days 2, 9 and 16.

Kaliberov, S., Stackhouse, M. A., Kaliberova, L., Zhou, T., & Buchsbaum, D. J. (2004). Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. Gene therapy, 11(8), 658-667.

Figure 7 Show binding activity of soluble TRAIL and TRA-8 to DR5 and DR4.

ELISA plates were coated with DR5/hIgG1 or DR4/hIgG1 and then incubated with TRAIL or TRA-8.

Figure 8 Soluble TRAIL and TRA-8 bind to DR5 and DR4.

ELISA plates were coated with DR5/hIgG1 or DR4/hIgG1 and then incubated with TRAIL or TRA-8.

Figure 9 Shows Flow cytometry analysis of the surface expression of DR5.

Figure 10 T cell lines were incubated with TRA-8 or murine IgG1 isotype control antibody followed by PE-conjugated goat anti-mouse IgG1.

Figure 1 Shows inhibitory activity of a monoclonal antibody against JFH-1-HCV upon infection with HCV.